Showing 2461-2470 of 5065 results for "".
New Clinical Guidelines for Nonmelanoma Skin Cancer Treatment; Arctics Biotherapeutics Seeks New FDA Approval for ZORYVE Foam
https://practicaldermatology.com/series/dermwire-tv/new-clinical-guidelines-for-nonmelanoma-skin-cancer-treatment-arctics-biotherapeutics-seeks-new-fda-approval-for-zoryve-foam/26745/In this week’s DermwireTV, new clinical guidelines for nonmelanoma skin cancer treatment; Arcutis Biotherapeutics seeks new FDA approval for ZORYVE foam; Practical Dermatology joins the ReachMD network; and the CEO of SofWave Medical joins us to discuss the company’s Ultrasound technology.Deep Dive: The Evolving Role of Nonsteroidal Topical Therapy for Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology/deep-dive-the-evolving-role-of-nonsteroidal-topical-therapy-for-atopic-dermatitis/57279/Walter J. Liszewski, MD, and Adelaide A. Hebert, MD, discuss nonsteroidal approaches to atopic dermatitis, including treatment simplification, pediatric use, remittive potential, quality-of-life considerations, and practical prescribing strategies.Prurigo Nodularis, Chronic Itch, and Lymphoma Risk
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/prurigo-nodularis-chronic-itch-and-lymphoma-risk/50965/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Lawrence Green, MD, FAAD, examine the link between prurigo nodularis, chronic pruritus, Type 2 inflammation, and lymphoma risk, with a focus on evaluating the underlying causes of persistent itch.Prurigo Nodularis in Skin of Color: Recognizing Distinct Clinical Presentations
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/prurigo-nodularis-in-skin-of-color-recognizing-distinct-clinical-presentations/57012/Cheri Frey, MD, discusses how prurigo nodularis may present differently in patients with skin of color, highlighting diagnostic challenges, variations in inflammation, and the importance of recognizing disease manifestations across diverse skin tones.Skin Biopsy for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/tbd/48782/James Q. Del Rosso, DO, FAOCD, discusses situations in which histopathology can help to correctly diagnose prurigo nodularis.Addressing Itch in Prurigo Nodularis Clinical Trials
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37170/Raja Sivamani, MD, MS, AP, an integrative dermatologist and Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis, addresses how future prurigo nodularis trials could better address the heterogeneity in disease burden and patient-reported outcomes.What’s New in Nonmelanoma Skin Cancers
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39735/Todd Schlesinger, MD, FAAD, talks about recent advances in diagnosis, therapy, and prevention of nonmelanoma skin cancers. This video was recorded at the Science of Skin Summit in Austin, TX.Non-Pharmacological Treatments for Skin Picking Disorder
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/non-pharmacological-treatments-for-skin-picking-disorder/33165/Peter Lio, MD, and Isabella Lewin explore a paper about non-pharmalogical options for skin picking disorder.Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.